TrialSignal transduction and targeted therapy2021

Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study.

Pingli Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.